Difference between revisions of "How I Treat"
Jump to navigation
Jump to search
m |
|||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | The "How I Treat" series has been published by ''Blood'' for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles. | + | The "How I Treat" series has been published by ''Blood'' for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles. While the vast majority of these are published in ''Blood'', there are a few exceptions. |
'''In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.''' | '''In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.''' | ||
| Line 32: | Line 32: | ||
**'''2020:''' DeWolf & Tallman. [https://doi.org/10.1182/blood.2019001982 How I treat relapsed or refractory AML] [https://pubmed.ncbi.nlm.nih.gov/32518943/ PubMed] | **'''2020:''' DeWolf & Tallman. [https://doi.org/10.1182/blood.2019001982 How I treat relapsed or refractory AML] [https://pubmed.ncbi.nlm.nih.gov/32518943/ PubMed] | ||
*'''2023:''' Biederstädt & Rezvani. [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed] | *'''2023:''' Biederstädt & Rezvani. [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed] | ||
| − | *'''2023:''' El Chaer et al. [ | + | *'''2023:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10447497/ How I treat AML incorporating the updated classifications and guidelines] [https://pubmed.ncbi.nlm.nih.gov/36758209/ PubMed] |
*'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/33171486/ PubMed] | *'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/33171486/ PubMed] | ||
*'''2021:''' Rubnitz & Kaspers. [https://doi.org/10.1182/blood.2021011694 How I treat pediatric acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/34115839/ PubMed] | *'''2021:''' Rubnitz & Kaspers. [https://doi.org/10.1182/blood.2021011694 How I treat pediatric acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/34115839/ PubMed] | ||
| Line 38: | Line 38: | ||
*'''2016:''' Ofran et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524532/ How I treat acute myeloid leukemia presenting with preexisting comorbidities] [https://pubmed.ncbi.nlm.nih.gov/27235136/ PubMed] | *'''2016:''' Ofran et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524532/ How I treat acute myeloid leukemia presenting with preexisting comorbidities] [https://pubmed.ncbi.nlm.nih.gov/27235136/ PubMed] | ||
*'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed] | *'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed] | ||
| − | *'''2016:''' Pratz & Levis. [ | + | *'''2016:''' Pratz & Levis. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5290983/ How I treat FLT3-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/27872057/ PubMed] |
*'''2015:''' Röllig & Ehninger. [http://www.bloodjournal.org/content/125/21/3246.long How I treat hyperleukocytosis in acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25778528/ PubMed] | *'''2015:''' Röllig & Ehninger. [http://www.bloodjournal.org/content/125/21/3246.long How I treat hyperleukocytosis in acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25778528/ PubMed] | ||
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed] | *'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed] | ||
| Line 51: | Line 51: | ||
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | *'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | ||
*'''2016:''' Gotlib. [https://doi.org/10.1182/blood-2016-08-693630 How I treat atypical chronic myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/27899359/ PubMed] | *'''2016:''' Gotlib. [https://doi.org/10.1182/blood-2016-08-693630 How I treat atypical chronic myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/27899359/ PubMed] | ||
| − | *'''2012:''' Cortes & Kantarjian. [ | + | *'''2012:''' Cortes & Kantarjian. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4916560/ How I treat newly diagnosed chronic phase CML] [https://pubmed.ncbi.nlm.nih.gov/22613793/ PubMed] |
| − | *'''2009:''' Radich. [ | + | *'''2009:''' Radich. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3654782/ How I monitor residual disease in chronic myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/19661271/ PubMed] |
===[[Chronic myelomonocytic leukemia|Chronic myelomonocytic leukemia (CMML)]]=== | ===[[Chronic myelomonocytic leukemia|Chronic myelomonocytic leukemia (CMML)]]=== | ||
| Line 58: | Line 58: | ||
===[[Hypereosinophilic syndrome|Hypereosinophilic syndrome (HES)]]=== | ===[[Hypereosinophilic syndrome|Hypereosinophilic syndrome (HES)]]=== | ||
| − | *'''2015:''' Klion. [ | + | *'''2015:''' Klion. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4551360/ How I treat hypereosinophilic syndromes] [https://pubmed.ncbi.nlm.nih.gov/25964669/ PubMed] |
===[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]=== | ===[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]=== | ||
*'''2024:''' Mina et al. [https://doi.org/10.1182/blood.2023023005 How I reduce and treat posttransplant relapse of MDS] [https://pubmed.ncbi.nlm.nih.gov/38306658/ PubMed] | *'''2024:''' Mina et al. [https://doi.org/10.1182/blood.2023023005 How I reduce and treat posttransplant relapse of MDS] [https://pubmed.ncbi.nlm.nih.gov/38306658/ PubMed] | ||
| Line 92: | Line 92: | ||
===[[Anaplastic large cell lymphoma]]=== | ===[[Anaplastic large cell lymphoma]]=== | ||
| − | *'''2018:''' Metha-Shah et al. [ | + | *'''2018:''' Metha-Shah et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6536699/ How I treat breast implant-associated anaplastic large cell lymphoma] [https://pubmed.ncbi.nlm.nih.gov/30209119/ PubMed] |
===[[Burkitt lymphoma|Burkitt lymphoma (BL)]]=== | ===[[Burkitt lymphoma|Burkitt lymphoma (BL)]]=== | ||
| − | *'''2018:''' Gopal & Gross. [ | + | *'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed] |
*'''2014:''' Jacobson & LaCasce. [https://doi.org/10.1182/blood-2014-06-538504 How I treat Burkitt lymphoma in adults] [https://pubmed.ncbi.nlm.nih.gov/25258344/ PubMed] | *'''2014:''' Jacobson & LaCasce. [https://doi.org/10.1182/blood-2014-06-538504 How I treat Burkitt lymphoma in adults] [https://pubmed.ncbi.nlm.nih.gov/25258344/ PubMed] | ||
===[[Castleman disease]]=== | ===[[Castleman disease]]=== | ||
| + | *'''2022:''' Brandstadter & Fajgenbaum. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9584165/ How we manage idiopathic multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/36125948/ PubMed] | ||
*'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed] | *'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed] | ||
| Line 105: | Line 106: | ||
*'''2019:''' Stephens & Byrd. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6428663/ How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia] | *'''2019:''' Stephens & Byrd. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6428663/ How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia] | ||
*'''2018:''' Brown. [https://doi.org/10.1182/blood-2017-08-764712 How I treat CLL patients with ibrutinib] [https://pubmed.ncbi.nlm.nih.gov/29255067/ PubMed] | *'''2018:''' Brown. [https://doi.org/10.1182/blood-2017-08-764712 How I treat CLL patients with ibrutinib] [https://pubmed.ncbi.nlm.nih.gov/29255067/ PubMed] | ||
| − | *'''2018:''' Gribben. [ | + | *'''2018:''' Gribben. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6034643/ How and when I do allogeneic transplant in CLL] [https://pubmed.ncbi.nlm.nih.gov/29752258/ PubMed] |
| − | *'''2017:''' Woyach. [ | + | *'''2017:''' Woyach. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5345730/ How I manage ibrutinib-refractory chronic lymphocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/28096090/ PubMed] |
| − | *'''2009:''' Gribben. [ | + | *'''2009:''' Gribben. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2941409/ How I treat CLL up front] [https://pubmed.ncbi.nlm.nih.gov/19850738/ PubMed] |
===[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]=== | ===[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]=== | ||
*'''2021:''' Epperla & Herrera. [https://doi.org/10.1182/blood.2020007900 How I incorporate novel agents into the treatment of classical Hodgkin lymphoma] | *'''2021:''' Epperla & Herrera. [https://doi.org/10.1182/blood.2020007900 How I incorporate novel agents into the treatment of classical Hodgkin lymphoma] | ||
*'''2015:''' Alinari & Blum. [https://doi.org/10.1182/blood-2015-10-671826 How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant] [https://pubmed.ncbi.nlm.nih.gov/26576863/ PubMed] | *'''2015:''' Alinari & Blum. [https://doi.org/10.1182/blood-2015-10-671826 How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant] [https://pubmed.ncbi.nlm.nih.gov/26576863/ PubMed] | ||
| − | *'''2014:''' Uldrick & Little. [ | + | *'''2014:''' Uldrick & Little. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4335078/ How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus] [https://pubmed.ncbi.nlm.nih.gov/25499453/ PubMed] |
===[[CNS lymphoma]]=== | ===[[CNS lymphoma]]=== | ||
*'''2023:''' Alderuccio et al. [https://doi.org/10.1182/blood.2023020168 How I treat secondary CNS involvement by aggressive lymphomas] [https://pubmed.ncbi.nlm.nih.gov/37702537/ PubMed] | *'''2023:''' Alderuccio et al. [https://doi.org/10.1182/blood.2023020168 How I treat secondary CNS involvement by aggressive lymphomas] [https://pubmed.ncbi.nlm.nih.gov/37702537/ PubMed] | ||
*'''2017:''' Chin & Cheah. [https://doi.org/10.1182/blood-2017-03-737460 How I treat patients with aggressive lymphoma at high risk of CNS relapse] [https://pubmed.ncbi.nlm.nih.gov/28611025/ PubMed] | *'''2017:''' Chin & Cheah. [https://doi.org/10.1182/blood-2017-03-737460 How I treat patients with aggressive lymphoma at high risk of CNS relapse] [https://pubmed.ncbi.nlm.nih.gov/28611025/ PubMed] | ||
| − | *'''2013:''' Rubenstein et al. [ | + | *'''2013:''' Rubenstein et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3790503/ How I treat CNS lymphomas] [https://pubmed.ncbi.nlm.nih.gov/23963042/ PubMed] |
===[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]=== | ===[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]=== | ||
| Line 133: | Line 134: | ||
===[[HIV-associated lymphoma]]=== | ===[[HIV-associated lymphoma]]=== | ||
| − | *'''2014:''' Uldrick & Little. [ | + | *'''2014:''' Uldrick & Little. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4335078/ How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus] [https://pubmed.ncbi.nlm.nih.gov/25499453/ PubMed] |
| − | *'''2012:''' Dunleavy & Wilson. [ | + | *'''2012:''' Dunleavy & Wilson. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3321851/ How I treat HIV-associated lymphoma] [https://pubmed.ncbi.nlm.nih.gov/22337719/ PubMed] |
*'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed] | *'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed] | ||
| Line 151: | Line 152: | ||
===[[Peripheral T-cell lymphoma|Peripheral T-cell lymphoma (PTCL)]]=== | ===[[Peripheral T-cell lymphoma|Peripheral T-cell lymphoma (PTCL)]]=== | ||
| − | *'''2014:''' Moskowitz et al. [ | + | *'''2014:''' Moskowitz et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4507040/ How I treat the peripheral T-cell lymphomas] [https://pubmed.ncbi.nlm.nih.gov/24615779/ PubMed] |
===[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]=== | ===[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]=== | ||
| Line 158: | Line 159: | ||
===[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBCL)]]=== | ===[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBCL)]]=== | ||
| − | *'''2018:''' Giulino-Roth. [ | + | *'''2018:''' Giulino-Roth. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6634954/ How I treat primary mediastinal B-cell lymphoma] [https://pubmed.ncbi.nlm.nih.gov/29976557/ PubMed] |
===[[T-cell prolymphocytic leukemia|Prolymphocytic leukemia (T-PLL)]]=== | ===[[T-cell prolymphocytic leukemia|Prolymphocytic leukemia (T-PLL)]]=== | ||
| Line 167: | Line 168: | ||
===[[Transformed lymphoma]]=== | ===[[Transformed lymphoma]]=== | ||
| − | *'''2014:''' Parikh et al. [ | + | *'''2014:''' Parikh et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3954047/ How we treat Richter syndrome] [https://pubmed.ncbi.nlm.nih.gov/24421328/ PubMed] |
===[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM)]]=== | ===[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM)]]=== | ||
| Line 183: | Line 184: | ||
===[[Multiple myeloma|Multiple myeloma (MM)]]=== | ===[[Multiple myeloma|Multiple myeloma (MM)]]=== | ||
| − | *'''2024:''' Facon et al. [ | + | *'''2024:''' Facon et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808246/ How I treat multiple myeloma in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/36693134/ PubMed] |
**'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed] | **'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed] | ||
*'''2023:''' van de Donk. [https://doi.org/10.1200/jco.22.02114 How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells] | *'''2023:''' van de Donk. [https://doi.org/10.1200/jco.22.02114 How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells] | ||
| Line 196: | Line 197: | ||
*'''2015:''' Larocca & Palumbo. [https://doi.org/10.1182/blood-2015-05-612960 How I treat fragile myeloma patients] [https://pubmed.ncbi.nlm.nih.gov/26324701/ PubMed] | *'''2015:''' Larocca & Palumbo. [https://doi.org/10.1182/blood-2015-05-612960 How I treat fragile myeloma patients] [https://pubmed.ncbi.nlm.nih.gov/26324701/ PubMed] | ||
*'''2015:''' Touzeau & Moreau. [https://doi.org/10.1182/blood-2015-07-635383 How I treat extramedullary myeloma] [https://pubmed.ncbi.nlm.nih.gov/26679866/ PubMed] | *'''2015:''' Touzeau & Moreau. [https://doi.org/10.1182/blood-2015-07-635383 How I treat extramedullary myeloma] [https://pubmed.ncbi.nlm.nih.gov/26679866/ PubMed] | ||
| − | *'''2014:''' Gertz & Dingli. [ | + | *'''2014:''' Gertz & Dingli. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4126328/ How we manage autologous stem cell transplantation for patients with multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/24973360/ PubMed] |
*'''2009:''' Stewart et al. [https://doi.org/10.1182/blood-2009-07-204651 How I treat multiple myeloma in younger patients] [https://pubmed.ncbi.nlm.nih.gov/19861683/ PubMed] | *'''2009:''' Stewart et al. [https://doi.org/10.1182/blood-2009-07-204651 How I treat multiple myeloma in younger patients] [https://pubmed.ncbi.nlm.nih.gov/19861683/ PubMed] | ||
===[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]=== | ===[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]=== | ||
| − | *'''2012:''' van de Donk et al. [ | + | *'''2012:''' van de Donk et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3757364/ How I treat plasma cell leukemia] [https://pubmed.ncbi.nlm.nih.gov/22837533/ PubMed] |
===[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]=== | ===[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]=== | ||
| − | *'''2014:''' Ghobrial & Landgren. [ | + | *'''2014:''' Ghobrial & Landgren. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4246036/ How I treat smoldering multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/25298034/ PubMed] |
==Histiocytic disorders== | ==Histiocytic disorders== | ||
| Line 210: | Line 211: | ||
===[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]=== | ===[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]=== | ||
| − | *'''2015:''' Allen et al. [ | + | *'''2015:''' Allen et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4492195/ How I treat Langerhans cell histiocytosis] [https://pubmed.ncbi.nlm.nih.gov/25827831/ PubMed] |
=Classical hematology= | =Classical hematology= | ||
==Hemostasis and thrombosis== | ==Hemostasis and thrombosis== | ||
| − | *'''2023:''' Samuelson Bannow & Konkle. [ | + | *'''2023:''' Samuelson Bannow & Konkle. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10562531/ How I approach bleeding in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/36652635/ PubMed] |
| − | *'''2021:''' Baker & O'Donnell. [ | + | *'''2021:''' Baker & O'Donnell. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9642789/ How I treat bleeding disorder of unknown cause] [https://pubmed.ncbi.nlm.nih.gov/34398949/ PubMed] |
| − | *'''2016:''' Martin & Key. [ | + | *'''2016:''' Martin & Key. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4946199/ How I treat patients with inherited bleeding disorders who need anticoagulant therapy] [https://pubmed.ncbi.nlm.nih.gov/27106121/ PubMed] |
*'''2015:''' Pavord & Maybury. [https://doi.org/10.1182/blood-2014-10-512608 How I treat postpartum hemorrhage] [https://pubmed.ncbi.nlm.nih.gov/25769619/ PubMed] | *'''2015:''' Pavord & Maybury. [https://doi.org/10.1182/blood-2014-10-512608 How I treat postpartum hemorrhage] [https://pubmed.ncbi.nlm.nih.gov/25769619/ PubMed] | ||
*'''2014:''' Johansson et al. [https://doi.org/10.1182/blood-2014-05-575340 How I treat patients with massive hemorrhage] [https://pubmed.ncbi.nlm.nih.gov/25293771/ PubMed] | *'''2014:''' Johansson et al. [https://doi.org/10.1182/blood-2014-05-575340 How I treat patients with massive hemorrhage] [https://pubmed.ncbi.nlm.nih.gov/25293771/ PubMed] | ||
| Line 223: | Line 224: | ||
*'''2022:''' Akwaa et al. [https://doi.org/10.1182/blood.2021014514 How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge] | *'''2022:''' Akwaa et al. [https://doi.org/10.1182/blood.2021014514 How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge] | ||
*'''2020:''' Ferrari & Peyvandi. [https://doi.org/10.1182/blood.2019000962 How I treat thrombotic thrombocytopenic purpura in pregnancy] | *'''2020:''' Ferrari & Peyvandi. [https://doi.org/10.1182/blood.2019000962 How I treat thrombotic thrombocytopenic purpura in pregnancy] | ||
| − | *'''2015:''' Sayani & Abrams. [ | + | *'''2015:''' Sayani & Abrams. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4473115/ How I treat refractory thrombotic thrombocytopenic purpura] [https://pubmed.ncbi.nlm.nih.gov/25784681/ PubMed] |
===[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APS)]]=== | ===[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APS)]]=== | ||
| Line 245: | Line 246: | ||
===[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]=== | ===[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]=== | ||
*'''2023:''' Doreille et al. [https://doi.org/10.1182/blood.2022015583 How I treat thrombotic microangiopathy in the era of rapid genomics] | *'''2023:''' Doreille et al. [https://doi.org/10.1182/blood.2022015583 How I treat thrombotic microangiopathy in the era of rapid genomics] | ||
| − | *'''2021:''' Thomas & Scully. [ | + | *'''2021:''' Thomas & Scully. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8555418/ How I treat microangiopathic hemolytic anemia in patients with cancer] |
===[[Venous thromboembolism|Venous thromboembolism (VTE)]]=== | ===[[Venous thromboembolism|Venous thromboembolism (VTE)]]=== | ||
| − | *'''2024:''' Bhat et al. [ | + | *'''2024:''' Bhat et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10862368/ How I treat pediatric venous thromboembolism in the DOAC era] [https://pubmed.ncbi.nlm.nih.gov/37390311/ PubMed] |
| − | **'''2017:''' Young. [ | + | **'''2017:''' Young. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed] |
*'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed] | *'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed] | ||
*'''2022:''' Schmidt & Lee. [https://doi.org/10.1182/blood.2019003689 How I treat and prevent venous thrombotic complications in patients with lymphoma] | *'''2022:''' Schmidt & Lee. [https://doi.org/10.1182/blood.2019003689 How I treat and prevent venous thrombotic complications in patients with lymphoma] | ||
| Line 258: | Line 259: | ||
*'''2019:''' Kraaijpoel & Carrier. [https://doi.org/10.1182/blood-2018-08-835595 How I treat cancer-associated venous thromboembolism] | *'''2019:''' Kraaijpoel & Carrier. [https://doi.org/10.1182/blood-2018-08-835595 How I treat cancer-associated venous thromboembolism] | ||
*'''2018:''' Rabinovich & Kahn. [https://doi.org/10.1182/blood-2018-01-785956 How I treat the postthrombotic syndrome] [https://pubmed.ncbi.nlm.nih.gov/29545327/ PubMed] | *'''2018:''' Rabinovich & Kahn. [https://doi.org/10.1182/blood-2018-01-785956 How I treat the postthrombotic syndrome] [https://pubmed.ncbi.nlm.nih.gov/29545327/ PubMed] | ||
| − | *'''2018:''' Shet & Wun. [ | + | *'''2018:''' Shet & Wun. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202908/ How I diagnose and treat venous thromboembolism in sickle cell disease] |
| − | *'''2018:''' Vedantham & Sista. [ | + | *'''2018:''' Vedantham & Sista. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5814931/ How I use catheter-directed interventional therapy to treat patients with venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/29295847/ PubMed] |
*'''2017:''' Schulman. [https://doi.org/10.1182/blood-2017-03-742304 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy] [https://pubmed.ncbi.nlm.nih.gov/28483766/ PubMed] | *'''2017:''' Schulman. [https://doi.org/10.1182/blood-2017-03-742304 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy] [https://pubmed.ncbi.nlm.nih.gov/28483766/ PubMed] | ||
*'''2015:''' Kyrle. [https://doi.org/10.1182/blood-2015-09-671297 How I treat recurrent deep-vein thrombosis] [https://pubmed.ncbi.nlm.nih.gov/26660685/ PubMed] | *'''2015:''' Kyrle. [https://doi.org/10.1182/blood-2015-09-671297 How I treat recurrent deep-vein thrombosis] [https://pubmed.ncbi.nlm.nih.gov/26660685/ PubMed] | ||
| Line 278: | Line 279: | ||
==Cytopenias== | ==Cytopenias== | ||
===Acquired pure red cell aplasia=== | ===Acquired pure red cell aplasia=== | ||
| − | *'''2021:''' Gurnari & Maciejewski. [ | + | *'''2021:''' Gurnari & Maciejewski. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8057257/ How I manage acquired pure red cell aplasia in adults] [https://pubmed.ncbi.nlm.nih.gov/33657207/ PubMed] |
===[[Anemia]]=== | ===[[Anemia]]=== | ||
| − | *'''2024:''' Oyedeji et al. [ | + | *'''2024:''' Oyedeji et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808247/ How I treat anemia in older adults] [https://pubmed.ncbi.nlm.nih.gov/36827619/ PubMed] |
| − | *'''2023:''' Carson & Brittenham. [ | + | *'''2023:''' Carson & Brittenham. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10485845/ How I treat anemia with red blood cell transfusion and iron] [https://pubmed.ncbi.nlm.nih.gov/36315909/ PubMed] |
| − | *'''2021:''' Gurnari & Maciejewski. [ | + | *'''2021:''' Gurnari & Maciejewski. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8057257/ How I manage acquired pure red cell aplasia in adults] |
*'''2020:''' Anand & Gupta. [https://doi.org/10.1182/blood.2019004004 How I treat anemia in heart failure] | *'''2020:''' Anand & Gupta. [https://doi.org/10.1182/blood.2019004004 How I treat anemia in heart failure] | ||
*'''2020:''' Fishbane & Coyne. [https://doi.org/10.1182/blood.2019004330 How I treat renal anemia] | *'''2020:''' Fishbane & Coyne. [https://doi.org/10.1182/blood.2019004330 How I treat renal anemia] | ||
| Line 325: | Line 326: | ||
*'''2024:''' James & Strouse [https://doi.org/10.1182/blood.2023020728 How I treat sickle cell disease in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37979134/ PubMed] | *'''2024:''' James & Strouse [https://doi.org/10.1182/blood.2023020728 How I treat sickle cell disease in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37979134/ PubMed] | ||
*'''2019:''' Stenger et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6923666/ How I treat sickle cell disease with hematopoietic cell transplantation] | *'''2019:''' Stenger et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6923666/ How I treat sickle cell disease with hematopoietic cell transplantation] | ||
| − | *'''2018:''' Pirenne & Yazdanbakhsh. [ | + | *'''2018:''' Pirenne & Yazdanbakhsh. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6014354/ How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions] [https://pubmed.ncbi.nlm.nih.gov/29724898/ PubMed] |
| − | *'''2018:''' Shet & Wun. [ | + | *'''2018:''' Shet & Wun. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202908/ How I diagnose and treat venous thromboembolism in sickle cell disease] |
| − | *'''2018:''' Thein & Howard. [ | + | *'''2018:''' Thein & Howard. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202910/ How I treat the older adult with sickle cell disease] |
| − | *'''2015:''' Anele et al. [ | + | *'''2015:''' Anele et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4458797/ How I treat priapism] [https://pubmed.ncbi.nlm.nih.gov/25810489/ PubMed] |
| − | *'''2015:''' Kassim et al. [ | + | *'''2015:''' Kassim et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4467906/ How I treat and manage strokes in sickle cell disease] [https://pubmed.ncbi.nlm.nih.gov/25824688/ PubMed] |
*'''2014:''' Sharpe & Thein. [https://doi.org/10.1182/blood-2014-02-557439 How I treat renal complications in sickle cell disease] [https://pubmed.ncbi.nlm.nih.gov/24764565/ PubMed] | *'''2014:''' Sharpe & Thein. [https://doi.org/10.1182/blood-2014-02-557439 How I treat renal complications in sickle cell disease] [https://pubmed.ncbi.nlm.nih.gov/24764565/ PubMed] | ||
==Hemolytic disorders== | ==Hemolytic disorders== | ||
| − | *'''2018:''' Machogu & Machado. [ | + | *'''2018:''' Machogu & Machado. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202915/ How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders] [https://pubmed.ncbi.nlm.nih.gov/30206115/ PubMed] |
*'''2017:''' Go et al. [https://doi.org/10.1182/blood-2016-11-693689 How I treat autoimmune hemolytic anemia] [https://pubmed.ncbi.nlm.nih.gov/28360039/ PubMed] | *'''2017:''' Go et al. [https://doi.org/10.1182/blood-2016-11-693689 How I treat autoimmune hemolytic anemia] [https://pubmed.ncbi.nlm.nih.gov/28360039/ PubMed] | ||
===[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]=== | ===[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]=== | ||
| Line 344: | Line 345: | ||
===[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]=== | ===[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]=== | ||
*'''2021:''' Brodsky. [https://doi.org/10.1182/blood.2019003812 How I treat paroxysmal nocturnal hemoglobinuria] | *'''2021:''' Brodsky. [https://doi.org/10.1182/blood.2019003812 How I treat paroxysmal nocturnal hemoglobinuria] | ||
| − | *'''2009:''' Brodsky. [ | + | *'''2009:''' Brodsky. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2710914/ How I treat paroxysmal nocturnal hemoglobinuria] [https://pubmed.ncbi.nlm.nih.gov/19372253/ PubMed] |
===[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]=== | ===[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]=== | ||
| Line 358: | Line 359: | ||
===Children=== | ===Children=== | ||
| − | *'''2024:''' Bhat et al. [ | + | *'''2024:''' Bhat et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10862368/ How I treat pediatric venous thromboembolism in the DOAC era] [https://pubmed.ncbi.nlm.nih.gov/37390311/ PubMed] |
| − | **'''2017:''' Young. [ | + | **'''2017:''' Young. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed] |
*'''2023:''' Myers et al. [https://doi.org/10.1182/blood.2022016937 How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL] [https://pubmed.ncbi.nlm.nih.gov/36416729/ PubMed] | *'''2023:''' Myers et al. [https://doi.org/10.1182/blood.2022016937 How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL] [https://pubmed.ncbi.nlm.nih.gov/36416729/ PubMed] | ||
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed] | *'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed] | ||
| Line 366: | Line 367: | ||
*'''2020:''' Teachey & O'Connor [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6966932/ How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children] [https://pubmed.ncbi.nlm.nih.gov/31738819/ PubMed] | *'''2020:''' Teachey & O'Connor [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6966932/ How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children] [https://pubmed.ncbi.nlm.nih.gov/31738819/ PubMed] | ||
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | *'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | ||
| − | *'''2018:''' Gopal & Gross. [ | + | *'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed] |
*'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed] | *'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed] | ||
*'''2012:''' Locatelli et al. [https://doi.org/10.1182/blood-2012-02-265884 How I treat relapsed childhood acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22896001/ PubMed] | *'''2012:''' Locatelli et al. [https://doi.org/10.1182/blood-2012-02-265884 How I treat relapsed childhood acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22896001/ PubMed] | ||
| Line 374: | Line 375: | ||
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | *'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | ||
*'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors] | *'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors] | ||
| − | *'''2018:''' Gopal & Gross. [ | + | *'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed] |
*'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed] | *'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed] | ||
===Older adults/Geriatric hematology=== | ===Older adults/Geriatric hematology=== | ||
| − | *'''2024:''' Facon et al. [ | + | *'''2024:''' Facon et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808246/ How I treat multiple myeloma in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/36693134/ PubMed] |
**'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed] | **'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed] | ||
*'''2024:''' Foy et al. [https://doi.org/10.1182/blood.2022017634 How I diagnose and treat thrombocytopenia in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/37956435/ PubMed] | *'''2024:''' Foy et al. [https://doi.org/10.1182/blood.2022017634 How I diagnose and treat thrombocytopenia in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/37956435/ PubMed] | ||
| − | *'''2024:''' Oyedeji et al. [ | + | *'''2024:''' Oyedeji et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808247/ How I treat anemia in older adults] [https://pubmed.ncbi.nlm.nih.gov/36827619/ PubMed] |
*'''2024:''' Poston & Kruse-Jarres [https://doi.org/10.1182/blood.2022018534 How I treat von Willebrand disorders in older adults] [https://pubmed.ncbi.nlm.nih.gov/37672774/ PubMed] | *'''2024:''' Poston & Kruse-Jarres [https://doi.org/10.1182/blood.2022018534 How I treat von Willebrand disorders in older adults] [https://pubmed.ncbi.nlm.nih.gov/37672774/ PubMed] | ||
*'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed] | *'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed] | ||
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism] | *'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism] | ||
| − | *'''2018:''' Thein & Howard. [ | + | *'''2018:''' Thein & Howard. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202910/ How I treat the older adult with sickle cell disease] |
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed] | *'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed] | ||
*'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed] | *'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed] | ||
| Line 396: | Line 397: | ||
===Cardiovascular complications=== | ===Cardiovascular complications=== | ||
| − | *'''2022:''' Herrmann et al. [ | + | *'''2022:''' Herrmann et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8914183/ How I treat cardiovascular complications in patients with lymphoid malignancies] [https://pubmed.ncbi.nlm.nih.gov/34752600/ PubMed] |
===[[Immune effector cells toxicity management]]=== | ===[[Immune effector cells toxicity management]]=== | ||
| Line 403: | Line 404: | ||
*'''2023:''' Jain et al. [https://doi.org/10.1182/blood.2022017415 How I treat cytopenias after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36800563/ PubMed] | *'''2023:''' Jain et al. [https://doi.org/10.1182/blood.2022017415 How I treat cytopenias after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36800563/ PubMed] | ||
*'''2023:''' Santomasso et al. [https://doi.org/10.1182/blood.2022017604 How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity] [https://pubmed.ncbi.nlm.nih.gov/36877916/ PubMed] | *'''2023:''' Santomasso et al. [https://doi.org/10.1182/blood.2022017604 How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity] [https://pubmed.ncbi.nlm.nih.gov/36877916/ PubMed] | ||
| − | *'''2020:''' Hill & Seo [ | + | *'''2020:''' Hill & Seo [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7441168/ How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies] |
===Infectious complications=== | ===Infectious complications=== | ||
| − | *'''2023:''' Dadwal et al. [ | + | *'''2023:''' Dadwal et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10163320/ How I prevent viral reactivation in high-risk patients] [https://pubmed.ncbi.nlm.nih.gov/36493341/ PubMed] |
| − | *'''2022:''' El Chaer et al. [ | + | *'''2022:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9249429/ How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies] [https://pubmed.ncbi.nlm.nih.gov/35776899/ PubMed] |
*'''2022:''' Law & Taplitz. [https://doi.org/10.1182/blood.2019003687 How I manage infection risk and prevention in patients with lymphoid cancer] [https://pubmed.ncbi.nlm.nih.gov/34748625/ PubMed] | *'''2022:''' Law & Taplitz. [https://doi.org/10.1182/blood.2019003687 How I manage infection risk and prevention in patients with lymphoid cancer] [https://pubmed.ncbi.nlm.nih.gov/34748625/ PubMed] | ||
| − | *'''2020:''' Hill & Seo. [ | + | *'''2020:''' Hill & Seo. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7441168/ How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies] |
| − | *'''2016:''' El Chaer et al. [ | + | *'''2016:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5146744/ How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients] [https://pubmed.ncbi.nlm.nih.gov/27760756/ PubMed] |
| − | *'''2016:''' Waghmare et al. [ | + | *'''2016:''' Waghmare et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4891952/ How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/26968533/ PubMed] |
*'''2014:''' Nucci & Anaissie. [https://doi.org/10.1182/blood-2014-04-516211 How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach] [https://pubmed.ncbi.nlm.nih.gov/25339358/ PubMed] | *'''2014:''' Nucci & Anaissie. [https://doi.org/10.1182/blood-2014-04-516211 How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach] [https://pubmed.ncbi.nlm.nih.gov/25339358/ PubMed] | ||
| Line 424: | Line 425: | ||
==Genetic risk== | ==Genetic risk== | ||
*'''2023:''' Hamilton et al. [https://doi.org/10.1182/blood.2022017379 How I communicate with patients and families about germ line genetic information] [https://pubmed.ncbi.nlm.nih.gov/37023453/ PubMed] | *'''2023:''' Hamilton et al. [https://doi.org/10.1182/blood.2022017379 How I communicate with patients and families about germ line genetic information] [https://pubmed.ncbi.nlm.nih.gov/37023453/ PubMed] | ||
| − | *'''2016:''' University of Chicago Hematopoietic Malignancies Cancer Risk Team [ | + | *'''2016:''' University of Chicago Hematopoietic Malignancies Cancer Risk Team [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813725/ How I diagnose and manage individuals at risk for inherited myeloid malignancies] [https://pubmed.ncbi.nlm.nih.gov/27471235/ PubMed] |
==Gynecologic considerations== | ==Gynecologic considerations== | ||
| Line 448: | Line 449: | ||
==Hospitalization== | ==Hospitalization== | ||
*'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed] | *'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed] | ||
| − | *'''2023:''' Samuelson Bannow & Konkle. [ | + | *'''2023:''' Samuelson Bannow & Konkle. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10562531/ How I approach bleeding in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/36652635/ PubMed] |
| − | *'''2023:''' Zon & Berliner. [ | + | *'''2023:''' Zon & Berliner. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10562528/ How I manage inpatient consultations for quantitative neutrophil abnormalities in adults] [https://pubmed.ncbi.nlm.nih.gov/36279420/ PubMed] |
*'''2012:''' Dobromirski & Cohen. [https://doi.org/10.1182/blood-2012-03-378901 How I manage venous thromboembolism risk in hospitalized medical patients] [https://pubmed.ncbi.nlm.nih.gov/22705598/ PubMed] | *'''2012:''' Dobromirski & Cohen. [https://doi.org/10.1182/blood-2012-03-378901 How I manage venous thromboembolism risk in hospitalized medical patients] [https://pubmed.ncbi.nlm.nih.gov/22705598/ PubMed] | ||
==Regional considerations== | ==Regional considerations== | ||
| − | *'''2018:''' Gopal & Gross. [ | + | *'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed] |
==Surgical considerations== | ==Surgical considerations== | ||
| Line 466: | Line 467: | ||
*'''2020:''' Puerta-Alcalde et al. [https://doi.org/10.1182/blood.2020005884 How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease] [https://pubmed.ncbi.nlm.nih.gov/33301030/ PubMed] | *'''2020:''' Puerta-Alcalde et al. [https://doi.org/10.1182/blood.2020005884 How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease] [https://pubmed.ncbi.nlm.nih.gov/33301030/ PubMed] | ||
*'''2019:''' McCurdy & Luznik. [https://doi.org/10.1182/blood.2019001323 How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide] [https://pubmed.ncbi.nlm.nih.gov/31751485/ PubMed] | *'''2019:''' McCurdy & Luznik. [https://doi.org/10.1182/blood.2019001323 How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide] [https://pubmed.ncbi.nlm.nih.gov/31751485/ PubMed] | ||
| − | *'''2018:''' Gribben. [ | + | *'''2018:''' Gribben. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6034643/ How and when I do allogeneic transplant in CLL] [https://pubmed.ncbi.nlm.nih.gov/29752258/ PubMed] |
*'''2017:''' Alvarnas et al. [https://doi.org/10.1182/blood-2017-04-551606 How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/28882882/ PubMed] | *'''2017:''' Alvarnas et al. [https://doi.org/10.1182/blood-2017-04-551606 How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/28882882/ PubMed] | ||
| − | *'''2017:''' Williams. [ | + | *'''2017:''' Williams. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5270387/ How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/27856461/ PubMed] |
| − | *'''2016:''' El Chaer et al. [ | + | *'''2016:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5146744/ How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients] [https://pubmed.ncbi.nlm.nih.gov/27760756/ PubMed] |
*'''2012:''' Wingard et al. [https://doi.org/10.1182/blood-2012-02-378976 How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/22692506/ PubMed] | *'''2012:''' Wingard et al. [https://doi.org/10.1182/blood-2012-02-378976 How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/22692506/ PubMed] | ||
===[[Autologous HSCT]]=== | ===[[Autologous HSCT]]=== | ||
| − | *'''2014:''' Gertz & Dingli. [ | + | *'''2014:''' Gertz & Dingli. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4126328/ How we manage autologous stem cell transplantation for patients with multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/24973360/ PubMed] |
===[[Graft versus host disease|Graft versus host disease (GVHD)]]=== | ===[[Graft versus host disease|Graft versus host disease (GVHD)]]=== | ||
| Line 480: | Line 481: | ||
*'''2020:''' Martin. [https://doi.org/10.1182/blood.2019000960 How I treat steroid-refractory acute graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/32202630/ PubMed] | *'''2020:''' Martin. [https://doi.org/10.1182/blood.2019000960 How I treat steroid-refractory acute graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/32202630/ PubMed] | ||
*'''2019:''' Sarantopoulos et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6418480/ How I treat refractory chronic graft-versus-host disease] | *'''2019:''' Sarantopoulos et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6418480/ How I treat refractory chronic graft-versus-host disease] | ||
| − | *'''2016:''' McDonald. [ | + | *'''2016:''' McDonald. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4807421/ How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver] [https://pubmed.ncbi.nlm.nih.gov/26729898/ PubMed] |
*'''2014:''' Flowers & Martin. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304105/ How we treat chronic graft-versus-host disease] | *'''2014:''' Flowers & Martin. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304105/ How we treat chronic graft-versus-host disease] | ||
*'''2012:''' Treister et al. [https://doi.org/10.1182/blood-2012-05-393389 How we treat oral chronic graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/22898605/ PubMed] | *'''2012:''' Treister et al. [https://doi.org/10.1182/blood-2012-05-393389 How we treat oral chronic graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/22898605/ PubMed] | ||
| − | *'''2007:''' Deeg. [ | + | *'''2007:''' Deeg. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc1885485/ How I treat refractory acute GVHD] [https://pubmed.ncbi.nlm.nih.gov/17234737/ PubMed] |
=Miscellaneous= | =Miscellaneous= | ||
| − | ==Acute respiratory failure= | + | ==Acute respiratory failure== |
*'''2024:''' Azoulay et al. [https://doi.org/10.1182/blood.2023021414 How I manage acute respiratory failure in patients with hematological malignancies] [https://pubmed.ncbi.nlm.nih.gov/38232056/ PubMed] | *'''2024:''' Azoulay et al. [https://doi.org/10.1182/blood.2023021414 How I manage acute respiratory failure in patients with hematological malignancies] [https://pubmed.ncbi.nlm.nih.gov/38232056/ PubMed] | ||
| Line 498: | Line 499: | ||
==Immunodeficiency== | ==Immunodeficiency== | ||
===Common variable immune deficiency (CVID)=== | ===Common variable immune deficiency (CVID)=== | ||
| − | *'''2010:''' Cunningham-Rundles. [ | + | *'''2010:''' Cunningham-Rundles. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2904582/ How I treat common variable immune deficiency] [https://pubmed.ncbi.nlm.nih.gov/20332369/ PubMed] |
===Severe combined immunodeficiency (SCID)=== | ===Severe combined immunodeficiency (SCID)=== | ||
*'''2013:''' Gaspar et al. [https://doi.org/10.1182/blood-2013-02-380105 How I treat severe combined immunodeficiency] [https://pubmed.ncbi.nlm.nih.gov/24113871/ PubMed] | *'''2013:''' Gaspar et al. [https://doi.org/10.1182/blood-2013-02-380105 How I treat severe combined immunodeficiency] [https://pubmed.ncbi.nlm.nih.gov/24113871/ PubMed] | ||
==Priapism== | ==Priapism== | ||
| − | *'''2015:''' Anele et al. [ | + | *'''2015:''' Anele et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4458797/ How I treat priapism] [https://pubmed.ncbi.nlm.nih.gov/25810489/ PubMed] |
==Protoporphyria== | ==Protoporphyria== | ||
*'''2023:''' Karp Leaf & Dickey. [https://doi.org/10.1182/blood.2022018688 How I treat erythropoietic protoporphyria and X-linked protoporphyria] [https://pubmed.ncbi.nlm.nih.gov/36898083/ PubMed] | *'''2023:''' Karp Leaf & Dickey. [https://doi.org/10.1182/blood.2022018688 How I treat erythropoietic protoporphyria and X-linked protoporphyria] [https://pubmed.ncbi.nlm.nih.gov/36898083/ PubMed] | ||
==T-cell chronic active Epstein-Barr virus disease (CAEBV)== | ==T-cell chronic active Epstein-Barr virus disease (CAEBV)== | ||
| − | *'''2018:''' Bollard & Cohen. [ | + | *'''2018:''' Bollard & Cohen. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6024635/ How I treat T-cell chronic active Epstein-Barr virus disease] [https://pubmed.ncbi.nlm.nih.gov/29712633/ PubMed] |
Latest revision as of 11:58, 25 June 2024
The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles. While the vast majority of these are published in Blood, there are a few exceptions.
In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
Malignant hematology
Acute leukemias
Mixed-phenotype acute leukemia (MPAL)
- 2015: Wolach & Stone. How I treat mixed-phenotype acute leukemia PubMed
Myeloid neoplasms
Acute lymphoblastic leukemia (ALL)
- 2023: Kopmar & Cassaday. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia PubMed
- 2023: Myers et al. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL PubMed
- 2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults PubMed
- 2020: Aldoss & Douer. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia PubMed
- 2020: Aldoss & Forman. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy PubMed
- 2020: Hunger & Raetz. How I treat relapsed acute lymphoblastic leukemia in the pediatric population PubMed
- 2020: Teachey & O'Connor How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children PubMed
- 2019: Ravandi. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia PubMed
- 2015: Curran & Stock. How I treat acute lymphoblastic leukemia in older adolescents and young adults PubMed
- 2015: Frey & Luger. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia PubMed
- 2015: Litzow & Ferrando. How I treat T-cell acute lymphoblastic leukemia in adults PubMed
- 2013: Gökbuget. How I treat older patients with ALL PubMed
- 2012: Locatelli et al. How I treat relapsed childhood acute lymphoblastic leukemia PubMed
- 2007: Rowe & Goldstone. How I treat acute lymphocytic leukemia in adults PubMed
Acute myeloid leukemia (AML)
- 2024: Thol et al. How I treat refractory and relapsed acute myeloid leukemia PubMed
- 2020: DeWolf & Tallman. How I treat relapsed or refractory AML PubMed
- 2023: Biederstädt & Rezvani. How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy PubMed
- 2023: El Chaer et al. How I treat AML incorporating the updated classifications and guidelines PubMed
- 2021: Falini et al. How I diagnose and treat NPM1-mutated AML PubMed
- 2021: Rubnitz & Kaspers. How I treat pediatric acute myeloid leukemia PubMed
- 2020: DiNardo & Wei. How I treat acute myeloid leukemia in the era of new drugs PubMed
- 2016: Ofran et al. How I treat acute myeloid leukemia presenting with preexisting comorbidities PubMed
- 2016: Peffault de Latour & Soulier. How I treat MDS and AML in Fanconi anemia PubMed
- 2016: Pratz & Levis. How I treat FLT3-mutated AML PubMed
- 2015: Röllig & Ehninger. How I treat hyperleukocytosis in acute myeloid leukemia PubMed
- 2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia PubMed
- 2011: Bakst et al. How I treat extramedullary acute myeloid leukemia PubMed
Acute promyelocytic leukemia (APL)
- 2014: Sanz & Motesinos. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia PubMed
- 2009: Tallman & Altman. How I treat acute promyelocytic leukemia PubMed
Chronic myeloid leukemia (CML)
- 2022: Berman. How I treat chronic-phase chronic myelogenous leukemia
- 2019: Hijiya & Suttorp. How I treat chronic myeloid leukemia in children and adolescents
- 2016: Gotlib. How I treat atypical chronic myeloid leukemia PubMed
- 2012: Cortes & Kantarjian. How I treat newly diagnosed chronic phase CML PubMed
- 2009: Radich. How I monitor residual disease in chronic myeloid leukemia PubMed
Chronic myelomonocytic leukemia (CMML)
- 2017: Solary & Itzykson. How I treat chronic myelomonocytic leukemia PubMed
Hypereosinophilic syndrome (HES)
- 2015: Klion. How I treat hypereosinophilic syndromes PubMed
Myelodysplastic syndrome (MDS)
- 2024: Mina et al. How I reduce and treat posttransplant relapse of MDS PubMed
- 2019: Santini. How I treat MDS after hypomethylating agent failure
- 2018: Locatelli & Strahm. How I treat myelodysplastic syndromes of childhood PubMed
- 2018: Steensma. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes PubMed
- 2016: Peffault de Latour & Soulier. How I treat MDS and AML in Fanconi anemia PubMed
- 2013: Sekeres & Cutler. How we treat higher-risk myelodysplastic syndromes PubMed
- 2013: Fenaux & Adès. How we treat lower-risk myelodysplastic syndromes
Myeloproliferative neoplasms (MPNs)
- 2024: Robinson et al. How I treat myeloproliferative neoplasms in pregnancy PubMed
- 2018: Odenike. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms PubMed
Essential thrombocythemia (ET)
- 2016: Rumi & Cazzola. How I treat essential thrombocythemia PubMed
Myelofibrosis (MF)
- 2023: Kröger et al. How I treat transplant-eligible patients with myelofibrosis PubMed
- 2018: Pardanani & Tefferi. How I treat myelofibrosis after failure of JAK inhibitors PubMed
- 2011: Tefferi. How I treat myelofibrosis PubMed
Polycythemia vera (PV)
- 2019: Spivak. How I treat polycythemia vera PubMed
- 2014: Vannucchi. How I treat polycythemia vera PubMed
Systemic mastocytosis
- 2013: Pardanani. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage) PubMed
Lymphoid neoplasms
Adult T-cell leukemia-lymphoma (ATLL)
- 2021: Cook & Phillips How I treat adult T-cell leukemia/lymphoma PubMed
Anaplastic large cell lymphoma
- 2018: Metha-Shah et al. How I treat breast implant-associated anaplastic large cell lymphoma PubMed
Burkitt lymphoma (BL)
- 2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa PubMed
- 2014: Jacobson & LaCasce. How I treat Burkitt lymphoma in adults PubMed
Castleman disease
- 2022: Brandstadter & Fajgenbaum. How we manage idiopathic multicentric Castleman disease PubMed
- 2010: Bower. How I treat HIV-associated multicentric Castleman disease PubMed
Chronic lymphocytic leukemia (CLL/SLL)
- 2021: Lew et al. How I treat chronic lymphocytic leukemia after venetoclax
- 2019: Stephens & Byrd. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
- 2018: Brown. How I treat CLL patients with ibrutinib PubMed
- 2018: Gribben. How and when I do allogeneic transplant in CLL PubMed
- 2017: Woyach. How I manage ibrutinib-refractory chronic lymphocytic leukemia PubMed
- 2009: Gribben. How I treat CLL up front PubMed
Classical Hodgkin lymphoma (cHL)
- 2021: Epperla & Herrera. How I incorporate novel agents into the treatment of classical Hodgkin lymphoma
- 2015: Alinari & Blum. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant PubMed
- 2014: Uldrick & Little. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus PubMed
CNS lymphoma
- 2023: Alderuccio et al. How I treat secondary CNS involvement by aggressive lymphomas PubMed
- 2017: Chin & Cheah. How I treat patients with aggressive lymphoma at high risk of CNS relapse PubMed
- 2013: Rubenstein et al. How I treat CNS lymphomas PubMed
Cutaneous T-cell lymphoma (CTCL)
- 2019: Shinohara & Shustov. How I treat primary cutaneous CD30 + lymphoproliferative disorders
- 2016: Whittaker et al. How I treat mycosis fungoides and Sézary syndrome PubMed
Diffuse large B-cell lymphoma (DLBCL)
- 2023: Lugtenburg & Mutsaers. How I treat older patients with DLBCL in the frontline setting PubMed
Follicular lymphoma (FL)
- 2019: Casulo & Barr. How I treat early-relapsing follicular lymphoma PubMed
High-grade B-cell lymphoma (HGBL)
- 2017: Friedberg. How I treat double-hit lymphoma PubMed
HIV-associated lymphoma
- 2014: Uldrick & Little. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus PubMed
- 2012: Dunleavy & Wilson. How I treat HIV-associated lymphoma PubMed
- 2010: Bower. How I treat HIV-associated multicentric Castleman disease PubMed
Large granular lymphocytic leukemia (T-LGL)
- 2011: Lamy & Loughran. How I treat LGL leukemia PubMed
Mantle cell lymphoma (MCL)
- 2009: Ghielmini & Zucca. How I treat mantle cell lymphoma PubMed
NK- and T-cell lymphoma (NKTCL)
- 2013: Tse & Kwong. How I treat NK/T-cell lymphomas PubMed
Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)
- 2020: Eichenauer & Engert. How I treat nodular lymphocyte-predominant Hodgkin Lymphoma
- 2013: Advani & Hoppe. How I treat nodular lymphocyte predominant Hodgkin lymphoma PubMed
Peripheral T-cell lymphoma (PTCL)
- 2014: Moskowitz et al. How I treat the peripheral T-cell lymphomas PubMed
Post-transplant lymphoproliferative disorder (PTLD)
- 2023: Amengual & Pro. How I treat posttransplant lymphoproliferative disorder PubMed
- 2015: Dierickx et al. How I treat posttransplant lymphoproliferative disorders PubMed
Primary mediastinal B-cell lymphoma (PMBCL)
- 2018: Giulino-Roth. How I treat primary mediastinal B-cell lymphoma PubMed
Prolymphocytic leukemia (T-PLL)
- 2012: Dearden. How I treat prolymphocytic leukemia PubMed
Splenic lymphoma
- 2011: Iannitto & Tripodo. How I diagnose and treat splenic lymphomas PubMed
Transformed lymphoma
- 2014: Parikh et al. How we treat Richter syndrome PubMed
Waldenström macroglobulinemia (WM)
- 2024: Treon et al. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia PubMed
- 2019: Dimopoulos & Kastritis. How I treat Waldenström macroglobulinemia PubMed
- 2015: Treon. How I treat Waldenström macroglobulinemia PubMed
Plasma cell dyscrasias
Light-chain (AL) amyloidosis
- 2022: Palladini & Merlini. How I treat AL amyloidosis
- 2012: Leung et al. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing PubMed
MGUS
- 2013: Fermand et al. How I treat monoclonal gammopathy of renal significance (MGRS) PubMed
Multiple myeloma (MM)
- 2024: Facon et al. How I treat multiple myeloma in geriatric patients PubMed
- 2010: Mehta et al. How I treat elderly patients with myeloma PubMed
- 2023: van de Donk. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells
- 2022: Kastritis et al. How I treat relapsed multiple myeloma
- 2014: Bladé et al. How I treat relapsed myeloma PubMed
- 2022: Perrot. How I treat frontline transplantation-eligible multiple myeloma PubMed
- 2022: Vaxman & Gertz. How I approach smoldering multiple myeloma
- 2022: Zamagni et al. How I treat high-risk multiple myeloma
- 2015: Lonial et al. How I treat high-risk myeloma PubMed
- 2017: Harousseau & Attal. How I treat first relapse of myeloma PubMed
- 2017: Moreau. How I treat myeloma with new agents PubMed
- 2015: Larocca & Palumbo. How I treat fragile myeloma patients PubMed
- 2015: Touzeau & Moreau. How I treat extramedullary myeloma PubMed
- 2014: Gertz & Dingli. How we manage autologous stem cell transplantation for patients with multiple myeloma PubMed
- 2009: Stewart et al. How I treat multiple myeloma in younger patients PubMed
Plasma cell leukemia (PCL)
- 2012: van de Donk et al. How I treat plasma cell leukemia PubMed
Smoldering multiple myeloma (SMM)
- 2014: Ghobrial & Landgren. How I treat smoldering multiple myeloma PubMed
Histiocytic disorders
Hemophagocytic lymphohistiocytosis (HLH)
- 2015: Schram & Berliner. How I treat hemophagocytic lymphohistiocytosis in the adult patient PubMed
Langerhans cell histiocytosis (LCH)
- 2015: Allen et al. How I treat Langerhans cell histiocytosis PubMed
Classical hematology
Hemostasis and thrombosis
- 2023: Samuelson Bannow & Konkle. How I approach bleeding in hospitalized patients PubMed
- 2021: Baker & O'Donnell. How I treat bleeding disorder of unknown cause PubMed
- 2016: Martin & Key. How I treat patients with inherited bleeding disorders who need anticoagulant therapy PubMed
- 2015: Pavord & Maybury. How I treat postpartum hemorrhage PubMed
- 2014: Johansson et al. How I treat patients with massive hemorrhage PubMed
- 2014: Levy & Goodnough. How I use fibrinogen replacement therapy in acquired bleeding PubMed
Acquired thrombotic thrombocytopenic purpura (aTTP)
- 2022: Akwaa et al. How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge
- 2020: Ferrari & Peyvandi. How I treat thrombotic thrombocytopenic purpura in pregnancy
- 2015: Sayani & Abrams. How I treat refractory thrombotic thrombocytopenic purpura PubMed
Antiphospholipid antibody syndrome (APS)
- 2024: Branch & Lim How I diagnose and treat antiphospholipid syndrome in pregnancy PubMed
- 2021: Cohen & Isenberg. How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome PubMed
- 2015: Ortel et al. How I treat catastrophic thrombotic syndromes PubMed
Arterial thromboembolism (ATE)
- 2020: May & Moll. How I treat unexplained arterial thrombosis
Disseminated intravascular coagulation (DIC)
- 2018: Levi & Scully. How I treat disseminated intravascular coagulation PubMed
Hemophilia
- 2020: Leebeek et al. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease
- 2019: Young. How I treat children with haemophilia and inhibitors
- 2015: Leissinger et al. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors PubMed
- 2012: Mannucci & Mancuso. How we choose factor VIII to treat hemophilia PubMed
Heparin-induced thrombocytopenia (HIT)
- 2016: Warkentin & Anderson. How I treat patients with a history of heparin-induced thrombocytopenia PubMed
Thrombotic microangiopathy (TMA)
- 2023: Doreille et al. How I treat thrombotic microangiopathy in the era of rapid genomics
- 2021: Thomas & Scully. How I treat microangiopathic hemolytic anemia in patients with cancer
Venous thromboembolism (VTE)
- 2024: Bhat et al. How I treat pediatric venous thromboembolism in the DOAC era PubMed
- 2017: Young. How I treat pediatric venous thromboembolism PubMed
- 2023: Akpan & Hunt. How I approach the prevention and treatment of thrombotic complications in hospitalized patients PubMed
- 2022: Schmidt & Lee. How I treat and prevent venous thrombotic complications in patients with lymphoma
- 2020: Klok & Huisman. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism
- 2020: Middeldorp & Ganzevoort. How I treat venous thromboembolism in pregnancy
- 2020: Wang & Carrier. How I treat obese patients with oral anticoagulants
- 2019: Pabinger & Thaler. How I treat patients with hereditary antithrombin deficiency
- 2019: Chan & Eikelbloom. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism
- 2019: Kraaijpoel & Carrier. How I treat cancer-associated venous thromboembolism
- 2018: Rabinovich & Kahn. How I treat the postthrombotic syndrome PubMed
- 2018: Shet & Wun. How I diagnose and treat venous thromboembolism in sickle cell disease
- 2018: Vedantham & Sista. How I use catheter-directed interventional therapy to treat patients with venous thromboembolism PubMed
- 2017: Schulman. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy PubMed
- 2015: Kyrle. How I treat recurrent deep-vein thrombosis PubMed
- 2015: O'Connell. How I treat incidental pulmonary embolism PubMed
- 2014: Ageno et al. How I treat splanchnic vein thrombosis PubMed
- 2014: Palareti. How I treat isolated distal deep vein thrombosis (IDDVT) PubMed
- 2012: Dobromirski & Cohen. How I manage venous thromboembolism risk in hospitalized medical patients PubMed
von Willebrand disease (vWD)
- 2024: Poston & Kruse-Jarres How I treat von Willebrand disorders in older adults PubMed
- 2020: Biguzzi et al. How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease
- 2020: Leebeek et al. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease
- 2019: Lavin & O'Donnell. How I treat low von Willebrand factor levels
- 2018: Kruse-Jarres & Johnsen. How I treat type 2B von Willebrand disease PubMed
- 2014: Tosetto & Castaman. How I treat type 2 variant forms of von Willebrand disease PubMed
- 2011: Tiede et al. How I treat the acquired von Willebrand syndrome PubMed
Cytopenias
Acquired pure red cell aplasia
- 2021: Gurnari & Maciejewski. How I manage acquired pure red cell aplasia in adults PubMed
Anemia
- 2024: Oyedeji et al. How I treat anemia in older adults PubMed
- 2023: Carson & Brittenham. How I treat anemia with red blood cell transfusion and iron PubMed
- 2021: Gurnari & Maciejewski. How I manage acquired pure red cell aplasia in adults
- 2020: Anand & Gupta. How I treat anemia in heart failure
- 2020: Fishbane & Coyne. How I treat renal anemia
- 2020: Gilreath & Rodgers. How I treat cancer-associated anemia
- 2020: Shander et al. How I treat anemia in the perisurgical setting
- 2016: Achebe & Gafter-Gvili. How I treat anemia in pregnancy: iron, cobalamin, and folate PubMed
- 2014: Hershko & Camaschella. How I treat unexplained refractory iron deficiency anemia
Aplastic anemia
- 2017: Bacigalupo. How I treat acquired aplastic anemia PubMed
Autoimmune cytopenia
- 2022: Porpaczy & Jäger. How I manage autoimmune cytopenias in patients with lymphoid cancer PubMed
Immune thrombocytopenia (ITP)
- 2021: Ghanima et al. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment
- 2016: Cuker & Neunert. How I treat refractory immune thrombocytopenia PubMed
Neutropenia & leukopenia
- 2014: Gibson & Berliner. How we evaluate and treat neutropenia in adults PubMed
Thrombocytopenia and platelet dysfunction
- 2024: Foy et al. How I diagnose and treat thrombocytopenia in geriatric patients PubMed
- 2024: Fogerty & Kuter How I treat thrombocytopenia in pregnancy PubMed
- 2012: Gernsheimer et al. How I treat thrombocytopenia in pregnancy PubMed
- 2023: Stanworth & Mumford. How I diagnose and treat neonatal thrombocytopenia PubMed
- 2022: Stanworth & Shah. How I use platelet transfusions PubMed
- 2022: Fiore et al. How I manage pregnancy in women with Glanzmann thrombasthenia
- 2021: Kyrle & Eichinger. How I manage cyclic thrombocytopenia
- 2016: Greinacher & Selleng. How I evaluate and treat thrombocytopenia in the intensive care unit patient PubMed
WHIM syndrome
- 2017: Badolato et al. How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome PubMed
Hemoglobinopathies
Beta thalassemia
- 2023: Saliba et al. How I treat non-transfusion-dependent β-thalassemia PubMed
- 2018: Taher & Cappellini. How I manage medical complications of β-thalassemia in adults PubMed
Sickle cell disease
- 2024: James & Strouse How I treat sickle cell disease in pregnancy PubMed
- 2019: Stenger et al. How I treat sickle cell disease with hematopoietic cell transplantation
- 2018: Pirenne & Yazdanbakhsh. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions PubMed
- 2018: Shet & Wun. How I diagnose and treat venous thromboembolism in sickle cell disease
- 2018: Thein & Howard. How I treat the older adult with sickle cell disease
- 2015: Anele et al. How I treat priapism PubMed
- 2015: Kassim et al. How I treat and manage strokes in sickle cell disease PubMed
- 2014: Sharpe & Thein. How I treat renal complications in sickle cell disease PubMed
Hemolytic disorders
- 2018: Machogu & Machado. How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders PubMed
- 2017: Go et al. How I treat autoimmune hemolytic anemia PubMed
Cold agglutinin disease (CAD)
- 2021: Berentsen. How I treat cold agglutinin disease
Atypical hemolytic uremic syndrome (aHUS)
- 2023: Fakhouri et al. How I diagnose and treat atypical hemolytic uremic syndrome PubMed
- 2014: Cataland & Wu. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome PubMed
Paroxysmal nocturnal hemoglobinuria (PNH)
- 2021: Brodsky. How I treat paroxysmal nocturnal hemoglobinuria
- 2009: Brodsky. How I treat paroxysmal nocturnal hemoglobinuria PubMed
Warm autoimmune hemolytic anemia (WAIHA)
- 2021: Barcellini & Fattizzo. How I treat warm autoimmune hemolytic anemia
Special considerations
Age-based recommendations
The majority of How I Treat articles focus on "standard" adults; below, articles that focus on other age populations are concatenated.
Neonates
- 2023: Stanworth & Mumford How I diagnose and treat neonatal thrombocytopenia PubMed
- 2018: Brown et al. How I treat infant leukemia PubMed
Children
- 2024: Bhat et al. How I treat pediatric venous thromboembolism in the DOAC era PubMed
- 2017: Young. How I treat pediatric venous thromboembolism PubMed
- 2023: Myers et al. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL PubMed
- 2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults PubMed
- 2021: Rubnitz & Kaspers. How I treat pediatric acute myeloid leukemia PubMed
- 2020: Hunger & Raetz. How I treat relapsed acute lymphoblastic leukemia in the pediatric population PubMed
- 2020: Teachey & O'Connor How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children PubMed
- 2019: Hijiya & Suttorp. How I treat chronic myeloid leukemia in children and adolescents
- 2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa PubMed
- 2018: Locatelli & Strahm. How I treat myelodysplastic syndromes of childhood PubMed
- 2012: Locatelli et al. How I treat relapsed childhood acute lymphoblastic leukemia PubMed
Adolescents and young adults (AYA)
- 2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults PubMed
- 2019: Hijiya & Suttorp. How I treat chronic myeloid leukemia in children and adolescents
- 2019: Young. How I treat children with haemophilia and inhibitors
- 2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa PubMed
- 2015: Curran & Stock. How I treat acute lymphoblastic leukemia in older adolescents and young adults PubMed
Older adults/Geriatric hematology
- 2024: Facon et al. How I treat multiple myeloma in geriatric patients PubMed
- 2010: Mehta et al. How I treat elderly patients with myeloma PubMed
- 2024: Foy et al. How I diagnose and treat thrombocytopenia in geriatric patients PubMed
- 2024: Oyedeji et al. How I treat anemia in older adults PubMed
- 2024: Poston & Kruse-Jarres How I treat von Willebrand disorders in older adults PubMed
- 2023: Lugtenburg & Mutsaers How I treat older patients with DLBCL in the frontline setting PubMed
- 2019: Chan & Eikelbloom. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism
- 2018: Thein & Howard. How I treat the older adult with sickle cell disease
- 2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia PubMed
- 2013: Gökbuget. How I treat older patients with ALL PubMed
Complications of treatment
Bleeding
- 2017: Boonyawat et al. How I treat heavy menstrual bleeding associated with anticoagulants PubMed
- 2014: Schulman & Furie. How I treat poisoning with vitamin K antagonists PubMed
- 2014: Siegal et al. How I treat target-specific oral anticoagulant-associated bleeding PubMed
Cardiovascular complications
- 2022: Herrmann et al. How I treat cardiovascular complications in patients with lymphoid malignancies PubMed
Immune effector cells toxicity management
- 2023: Gutierrez et al. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy PubMed
- 2023: Jain et al. How I treat refractory CRS and ICANS after CAR T-cell therapy PubMed
- 2023: Jain et al. How I treat cytopenias after CAR T-cell therapy PubMed
- 2023: Santomasso et al. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity PubMed
- 2020: Hill & Seo How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Infectious complications
- 2023: Dadwal et al. How I prevent viral reactivation in high-risk patients PubMed
- 2022: El Chaer et al. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies PubMed
- 2022: Law & Taplitz. How I manage infection risk and prevention in patients with lymphoid cancer PubMed
- 2020: Hill & Seo. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
- 2016: El Chaer et al. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients PubMed
- 2016: Waghmare et al. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation PubMed
- 2014: Nucci & Anaissie. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach PubMed
Iron overload
- 2012: Hoffbrand et al. How I treat transfusional iron overload PubMed
Medication toxicities
- 2017: Delforge & Ludwig. How I manage the toxicities of myeloma drugs PubMed
Neurologic medications
- 2022: Nayak & Batchelor. How I treat neurologic complications in patients with lymphoid cancer PubMed
Genetic risk
- 2023: Hamilton et al. How I communicate with patients and families about germ line genetic information PubMed
- 2016: University of Chicago Hematopoietic Malignancies Cancer Risk Team How I diagnose and manage individuals at risk for inherited myeloid malignancies PubMed
Gynecologic considerations
Menstruation
- 2017: Boonyawat et al. How I treat heavy menstrual bleeding associated with anticoagulants PubMed
Pregnancy
- 2024: Branch & Lim How I diagnose and treat antiphospholipid syndrome in pregnancy PubMed
- 2024: Fogerty & Kuter How I treat thrombocytopenia in pregnancy PubMed
- 2012: Gernsheimer et al. How I treat thrombocytopenia in pregnancy PubMed
- 2024: James & Strouse How I treat sickle cell disease in pregnancy PubMed
- 2024: Robinson et al. How I treat myeloproliferative neoplasms in pregnancy PubMed
- 2022: Fiore et al. How I manage pregnancy in women with Glanzmann thrombasthenia
- 2020: Dunleavy & McLintock. How I treat lymphoma in pregnancy
- 2020: Ferrari & Peyvandi. How I treat thrombotic thrombocytopenic purpura in pregnancy
- 2020: Leebeek et al. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease
- 2020: Middeldorp & Ganzevoort. How I treat venous thromboembolism in pregnancy
- 2016: Achebe & Gafter-Gvili. How I treat anemia in pregnancy: iron, cobalamin, and folate PubMed
- 2013: Milojkovic & Apperley. How I treat leukemia during pregnancy PubMed
Postpartum period
- 2015: Pavord & Maybury. How I treat postpartum hemorrhage PubMed
Hospitalization
- 2023: Akpan & Hunt. How I approach the prevention and treatment of thrombotic complications in hospitalized patients PubMed
- 2023: Samuelson Bannow & Konkle. How I approach bleeding in hospitalized patients PubMed
- 2023: Zon & Berliner. How I manage inpatient consultations for quantitative neutrophil abnormalities in adults PubMed
- 2012: Dobromirski & Cohen. How I manage venous thromboembolism risk in hospitalized medical patients PubMed
Regional considerations
- 2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa PubMed
Surgical considerations
- 2020: Shander et al. How I treat anemia in the perisurgical setting
- 2012: Spyropoulos & Douketis. How I treat anticoagulated patients undergoing an elective procedure or surgery PubMed
Transplantation
Allogeneic HSCT
- 2024: Mina et al. How I reduce and treat posttransplant relapse of MDS PubMed
- 2023: DeFilipp & Chen. How I treat with maintenance therapy after allogeneic HCT PubMed
- 2021: Burns & Morris. How I use allogeneic HSCT for adults with inborn errors of immunity PubMed
- 2020: Puerta-Alcalde et al. How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease PubMed
- 2019: McCurdy & Luznik. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide PubMed
- 2018: Gribben. How and when I do allogeneic transplant in CLL PubMed
- 2017: Alvarnas et al. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation PubMed
- 2017: Williams. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation PubMed
- 2016: El Chaer et al. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients PubMed
- 2012: Wingard et al. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation PubMed
Autologous HSCT
- 2014: Gertz & Dingli. How we manage autologous stem cell transplantation for patients with multiple myeloma PubMed
Graft versus host disease (GVHD)
- 2023: Cooper & Abkowitz. How I diagnose and treat acute graft-versus-host disease after solid organ transplantation
- 2023: Rimando et al. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond
- 2020: Martin. How I treat steroid-refractory acute graft-versus-host disease PubMed
- 2019: Sarantopoulos et al. How I treat refractory chronic graft-versus-host disease
- 2016: McDonald. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver PubMed
- 2014: Flowers & Martin. How we treat chronic graft-versus-host disease
- 2012: Treister et al. How we treat oral chronic graft-versus-host disease PubMed
- 2007: Deeg. How I treat refractory acute GVHD PubMed
Miscellaneous
Acute respiratory failure
- 2024: Azoulay et al. How I manage acute respiratory failure in patients with hematological malignancies PubMed
Atrial fibrillation
- 2016: Steinberg. How I use anticoagulation in atrial fibrillation PubMed
Cryoglobulinemia
- 2016: Muchtar et al. How I treat cryoglobulinemia PubMed
Immunodeficiency
Common variable immune deficiency (CVID)
- 2010: Cunningham-Rundles. How I treat common variable immune deficiency PubMed
Severe combined immunodeficiency (SCID)
- 2013: Gaspar et al. How I treat severe combined immunodeficiency PubMed
Priapism
- 2015: Anele et al. How I treat priapism PubMed
Protoporphyria
- 2023: Karp Leaf & Dickey. How I treat erythropoietic protoporphyria and X-linked protoporphyria PubMed
T-cell chronic active Epstein-Barr virus disease (CAEBV)
- 2018: Bollard & Cohen. How I treat T-cell chronic active Epstein-Barr virus disease PubMed